Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Sep 22:16:1649046.
doi: 10.3389/fimmu.2025.1649046. eCollection 2025.

STING pathways and Sjögren's syndrome: Exploration from mechanism to treatment

Yuxiu Ka #  1   2 , Tingting Tan #  3 , Yihua Fan  4 , Wei Liu  1   2 , Aihua Wang  5 , Wen Wang  1   2 , Gesang Yuzhen  1   2 , JingYi Zhang  1   2 , Xiaoge Yao  1   2 , Xueying Lin  1   2 , Yuanhao Wu  1   2
Affiliations
Review

STING pathways and Sjögren's syndrome: Exploration from mechanism to treatment

Yuxiu Ka et al. Front Immunol. .

Abstract

Sjögren's syndrome (SS) is an autoimmune disease characterized by abnormal lymphocyte proliferation and progressive exocrine gland dysfunction. The Stimulator of Interferon Genes (STING) pathways, as an important intracellular immune hub, overactivation can drive abnormally high expression of type I interferon and induce inflammatory cell infiltration, which is considered an important mechanism in the pathogenesis of SS. However, currently there is limited clinical evidence for direct activation of STING in human SS, and its tissue-specific regulatory mechanisms in target organs also need to be further elucidated. Based on this, STING pathway inhibitors have shown potential value in treating SS. This article systematically reviews the molecular mechanisms of the STING pathways in the pathogenesis of SS, explores its feasibility as a therapeutic target, and provides new evidence and ideas for precision treatment of SS.

Keywords: CGAS; STING inhibitor; STING pathways; Sjögren’s syndrome; review.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Interferon gene-stimulated receptor (STING) signaling pathway and its regulation.
See this image and copyright information in PMC

References

    1. Ramos-Casals M, Brito-Zeron P, Bombardieri S, Bootsma H, De Vita S, Dorner T, et al. EULAR recommendations for the management of Sjogren’s syndrome with topical and systemic therapies. Ann Rheum Dis. (2020) 79:3–18. doi: 10.1136/annrheumdis-2019-216114, PMID: - DOI - PubMed
    1. Baldini C, Fulvio G, La Rocca G, Ferro F. Update on the pathophysiology and treatment of primary Sjogren syndrome. Nat Rev Rheumatol. (2024) 20:473–91. doi: 10.1038/s41584-024-01135-3, PMID: - DOI - PubMed
    1. Thorlacius GE, Bjork A, Wahren-Herlenius M. Genetics and epigenetics of primary Sjogren syndrome: implications for future therapies. Nat Rev Rheumatol. (2023) 19:288–306. doi: 10.1038/s41584-023-00932-6, PMID: - DOI - PMC - PubMed
    1. Beydon M, McCoy S, Nguyen Y, Sumida T, Mariette X, Seror R. Epidemiology of sjogren syndrome. Nat Rev Rheumatol. (2024) 20:158–69. doi: 10.1038/s41584-023-01057-6, PMID: - DOI - PubMed
    1. Perricone C, Bruno L, Cafaro G, Latini A, Ceccarelli F, Borgiani P, et al. Sjogren’s syndrome: Everything you always wanted to know about genetic and epigenetic factors. Autoimmun Rev. (2024) 23:103673. doi: 10.1016/j.autrev.2024.103673, PMID: - DOI - PubMed

MeSH terms